Yes, IV lignocaine (lidocaine) can cause seizures, particularly at plasma concentrations above therapeutic levels or when administered too rapidly.
Seizures are a well-recognized manifestation of central nervous system toxicity from intravenous lidocaine, occurring when plasma levels exceed the narrow therapeutic window. 1, 2
Mechanism and Risk Profile
Lidocaine has a low therapeutic index, with CNS toxicity starting at plasma levels only slightly higher than therapeutic concentrations 1. The drug affects multiple receptor types at near-toxic concentrations, including voltage-gated sodium channels, NMDA receptors, and numerous other CNS targets 1.
Key Clinical Features:
- Concentration-dependent effect: At lower concentrations, lidocaine has anticonvulsant properties; above 15 μg/mL, it frequently causes seizures 3
- Seizure characteristics: Despite experimental models showing focal onset in the amygdala, clinical seizures from IV lidocaine are almost invariably generalized without clear focal signs 3
- Non-linear correlation: The relationship between plasma levels and toxicity symptoms is unpredictable, reflecting complex interactions between patient factors and drug pharmacokinetics 1
Clinical Presentation Spectrum
CNS toxicity manifests as a progression of symptoms 2:
Early warning signs:
- Light-headedness, nervousness
- Peri-oral numbness, metallic taste
- Tinnitus
- Drowsiness (often the first sign of high blood levels)
Progressive toxicity:
- Muscle twitching, tremors
- Confusion, slurred speech
- Convulsions/seizures
- Loss of consciousness
- Respiratory depression and arrest
Evidence from Clinical Practice
The 2021 international consensus statement [1-1] was developed specifically after a patient death following IV lidocaine administration, highlighting real-world toxicity risks. In clinical trials:
- 50 of 68 studies reported adverse events 1
- Minor effects (drowsiness, dizziness, peri-oral numbness, tinnitus) occurred in 6.8% of 544 patients 1
- Catastrophic events are usually due to dosing errors, infusion programming mistakes, or wrong drug administration 1
Critical Safety Measures to Prevent Seizures
Dosing parameters 1:
- Loading dose: ≤1.5 mg/kg (ideal body weight) over 10 minutes
- Maintenance: ≤1.5 mg/kg/h for maximum 24 hours
- Absolute maximum: 120 mg/h regardless of weight
- Do NOT use in patients <40 kg
Monitoring requirements 1:
- Patients outside operating theatre/recovery should be in monitored high-dependency unit (level 2 care)
- Continuous vigilance for toxicity signs
- Lipid emulsion 20% must be immediately available wherever lidocaine is used
- Staff must know its location and administration protocol
Contraindications requiring caution 1:
- Seizure disorders (relative contraindication)
- Cardiac disease
- Hepatic or renal impairment
- Electrolyte disorders
Special Populations at Higher Risk
Dravet syndrome: A case report documented generalized tonic-clonic seizure immediately following IV lidocaine bolus 4. Sodium channel blockers can worsen seizures in this genetic epilepsy.
Localization-related epilepsy: Complex partial seizures may evolve to secondarily generalized seizures after lidocaine administration 5.
Paradoxical Use in Seizure Management
Interestingly, lidocaine has been used successfully as an anti-seizure medication in specific contexts:
- Neonatal seizures refractory to phenobarbital showed significant seizure burden reduction 6
- Pediatric FIRES (febrile infection-related epilepsy syndrome) responded to prolonged lidocaine infusion 7
This dual nature underscores the critical importance of dose, rate of administration, and patient selection.
Management of Lidocaine-Induced Seizures
Immediate actions 2:
- Ensure patent airway and oxygen administration
- Assisted/controlled ventilation with positive pressure capability
- If seizures persist despite respiratory support: small increments of ultra-short acting barbiturate (thiopental) or benzodiazepine (diazepam) IV
- Lipid emulsion therapy per LAST protocols
- Supportive circulatory management with IV fluids ± vasopressors
Critical pitfall: Clinicians must maintain high index of suspicion for toxicity even when other explanations for symptoms exist 1.
Bottom Line
The narrow therapeutic window means that even appropriately dosed lidocaine can cause seizures if patient-specific factors (hepatic dysfunction, drug interactions, low body weight) increase plasma concentrations unpredictably. The correlation between plasma levels and symptoms is not linear 1, making clinical vigilance paramount. Use ideal body weight for calculations, never exceed recommended doses, ensure proper monitoring, and have lipid emulsion immediately available.